Emir Sokolović, Medical Oncology Resident at Clinical Center University of Sarajevo, shared on LinkedIn:
“Another great collaborative effort from an excellent team!
In advanced biliary tract cancer, distinguishing treatment-related toxicity from disease-related complications is essential for optimizing treatment safety and guiding everyday clinical decisions.”
Title: Practical considerations for the safe use of pembrolizumab or durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer
Authors: Enes Erul, Sergio Cifuentes-Canaval, Emir Sokolović, Akhil Santhosh, Luis Gabriel Parra-Lara, Fernando Sabino Marques Monteiro, Raffaella Massafra, Oronzo Brunetti, Francesco Ciccimarra, Gerardo Cazzato, Antonella Daniele, Chiara Paciolla, Pinar Kubilay Tolunay, Alessandro Rizzo.
Read the full article.
Key Takeaways
- Pembrolizumab or durvalumab combined with gemcitabine and cisplatin are first-line treatment options for eligible patients with advanced biliary tract cancer, although no direct safety comparison between the two has been conducted.
- Severe side effects are common with both regimens, mostly due to chemotherapy, while immunotherapy introduces additional immune-related risks.
- Biliary obstruction, stents, infections, liver problems, and frailty can make it difficult to identify the actual cause of treatment-related complications.
- Safe treatment requires regular monitoring, proper management of biliary complications, infection control, and a multidisciplinary approach.
- More real-world research is needed in patient groups not well represented in KEYNOTE-966 and TOPAZ-1, particularly those with elevated bilirubin or poor performance status.
You may also be interested in: Advanced Biliary Tract Cancer: Real-World Outcomes of First-Line Chemoimmunotherapy and Subsequent Targeted Therapy
